Citations

Clear

13 citation(s) found for "Smith, Brian J".

Risk of cardiovascular disease in people with narcolepsy: a plain language summary of publication
Black, Jed , Smith, R. Brian, Dabrowski, Elizabeth , Taylor, Ben , Somers, Virend K.

Mayo Clinic

Future Cardiology | April 3, 2025 | Volume: 21 | Issue: 6 | Pages: 339-348

10.1080/14796678.2025.2482383 | PMID 40176411 Get It

Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM
Petronek, Michael S. , Monga, Varun , Bodeker, Kellie L. , Kwofie, Michael , Lee, Chu‐Yu , Stolwijk, Jeffrey M. , Zaher, Amira , Wagner, Brett A. , Smith, Mark C. , Vollstedt, Sandy , Brown, Heather , Chandler, Meghan L. , Lorack, Amanda C. , Wulfekuhle, Jared S. , Flynn, Ryan T. , Jones, Karra A. , Magnotta, Vincent A. , Mapuskar, Kranti A , Stolwijk, Jeffrey M , Zaher, Amira , Wagner, Brett A , Smith, Mark C , Vollstedt, Sandy , Brown, Heather , Chandler, Meghan L , Lorack, Amanda C , Wulfekuhle, Jared S , Sarkaria, Jann N , Flynn, Ryan T , Greenlee, Jeremy D W , Howard, Matthew A , Smith, Brian J , Jones, Karra A , Buettner, Garry R , Cullen, Joseph J , St-Aubin, Joel , Buatti, John M , Magnotta, Vincent A , Spitz, Douglas R , Allen, Bryan G , Monga, Varun , Mapuskar, Kranti A. , Sarkaria, Jann N. , Greenlee, Jeremy D.W. , Howard, Matthew A. , Buettner, Garry R. , Buatti, John M. , Spitz, Douglas R.

Mayo Clinic

Clinical Cancer Research | September 29, 2023 | Volume: 30 | Issue: 2 | Pages: 283-293

10.1158/1078-0432.ccr-22-3952 | PMID 37773633 Get It

Abstract Purpose: Pharmacologic ascorbate (P-AscH−) is hypothesized to be an iron (Fe)-dependent tumor-specific adjuvant to chemoradiation in treating glioblastoma (GBM). This study determined the efficacy of combining P-AscH− with radiation and temozolomide in a phase II clinical trial while simultaneously investigating a mechanism-based, noninvasive biomarker in T2* mapping to predict GBM response to P-AscH− in humans. Patients and Methods: The single-arm phase II clinical trial (NCT02344355) enrolled 55 subjects, with analysis performed 12 months following the completion of treatment. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan–Meier method and compared across patient subgroups with log-rank tests. Forty-nine of 55 subjects were evaluated using T2*-based MRI to assess its utility as an Fe-dependent biomarker. Results: Median OS was estimated to be 19.6 months [90% confidence interval (CI), 15.7–26.5 months], a statistically significant increase compared with historic control patients (14.6 months). Subjects with initial T2* relaxation < 50 ms were associated with a significant increase in PFS compared with T2*-high subjects (11.2 months vs. 5.7 months, P < 0.05) and a trend toward increased OS (26.5 months vs. 17.5 months). These results were validated in preclinical in vitro and in vivo model systems. Conclusions: P-AscH− combined with temozolomide and radiotherapy has the potential to significantly enhance GBM survival. T2*-based MRI assessment of tumor iron content is a prognostic biomarker for GBM clinical outcomes. See related commentary by Nabavizadeh and Bagley, p. 255
An exploratory study of plasma ceramides in comorbidities in Down syndrome
Worley, Gordon , Byeon, Seul Kee , Smith, P. Brian , Hart, Sarah J. , Young, Sarah P. , Pandey, Akhilesh , Pandey, Akhilesh , Byeon, Seul Kee , Kishnani, Priya Sunil

Mayo Clinic

American Journal of Medical Genetics Part A | June 21, 2023 | Volume: 191 | Issue: 9 | Pages: 2300-2311

10.1002/ajmg.a.63325 | PMID 37340831 Get It

AbstractPlasma ceramide levels (henceforth, “ceramides”) are biomarkers of some diseases that are comorbidities of Down syndrome (DS). We sought to determine if comorbidities in DS were associated with ceramides, studying a convenience cohort of 35 study participants, all ≥12 months old. To identify comorbidities, we reviewed the problem lists in electronic health records that were concurrent with sample collection. We placed clinically related comorbidities into one of five categories of comorbidities, henceforth, categories: obesity/overweight; autoimmune disease; congenital heart disease; bacterial infection; and central nervous system (CNS) condition. We measured the eight ceramides most frequently associated with disease using liquid chromatography–tandem mass spectrometry. We calculated a ceramide composite outcome score (CCOS) for each participant by normalizing each ceramide level to the mean for that level in the study population and then summing the normalized levels, to be proxy variable for all eight ceramides in aggregate. We used multivariable linear regression models adjusted for age and sex to test associations of categories with ceramides and with CCOSs. Post hoc,we realized that co‐occurring comorbidities might interfere with establishing associations between predictor categories and ceramides and that stratified analyses might eliminate their influence on associations. We posited that CCOSs could be used to screen for associations of categories with multiple ceramides, since most diseases have been associated with more than one ceramide. We chose to omit in the stratified analyses the two categories that were the most different from one another in their associations with their CCOSs, having the most divergent regression coefficients (the highest positive and lowest negative coefficients). We first omitted one of these two divergent categories in a stratified analysis and tested in the remaining participants (those without a comorbidity in the interfering category) for associations of the other four categories with their CCOSs and then did the same for the other divergent category. In each of these two screening stratified analyses, we found one category was significantly associated with its CCOS. In the two identified categories, we then tested for associations with each of the eight ceramides, using the appropriate stratified analysis. Next, we sought to determine if the associations of the two categories with ceramides we found by omitting participants in the interfering categories held in our small sample for participants in the omitted categories as well. For each of the two categories, we therefore omitted participantswithoutthe interfering category and determined associations between the predictor category and individual ceramides in the remaining participants (thosewitha comorbidity in the interfering category). In the a priori analyses, autoimmune disease was inversely associated with C16 and CNS condition was inversely associated with C23. Obesity/overweight and CNS condition were the two categories with the most divergent regression coefficients (0.037 vs. −0.048). In post hoc stratified analyses, after omitting participants with obesity/overweight, thereby leaving participantswithoutobesity/overweight, bacterial infection was associated with its CCOS and then with C14, C20, and C22. However, in the companion stratified analyses, omitting participants without obesity/overweight, thereby leaving participantswithobesity/overweight, bacterial infection was not associated with any of the eight ceramides. Similarly, in post hoc stratified analyses after omitting participants with a CNS condition, thereby leaving participantswithouta CNS condition, obesity/overweight was associated with its CCOS and then with C14, C23, and C24. In the companion analyses, omitting participants without a CNS condition, thereby leaving participantswitha CNS condition, obesity/overweight was inversely associated with C24.1. In conclusion, CNS and autoimmune disease were inversely associated with one ceramide each in a priori analyses. In post hoc analyses, we serendipitously omitted categories that interfered with associations of other categories with ceramides in stratified analyses. We found that bacterial infection was associated with three ceramides in participants without obesity/overweight and that obesity/overweight was associated with three ceramides in participants without a CNS condition. We therefore identified obesity/overweight and CNS conditions as potential confounders or effect modifiers for these associations. This is the first report of ceramides in DS and in human bacterial infection. Further study of ceramides in comorbidities of DS is justified.
Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS)
Kang, Daniel , Coffey, Christopher S. , Smith, Brian J, Yuan, Ying , Shi, Qian , Yin, Jun , Shi, Qian , Smith, Brian J

Mayo Clinic

Statistics in Medicine | March 27, 2021 | Volume: 40 | Issue: 12 | Pages: 2893-2921

10.1002/sim.8946 | PMID 33772843 Get It

Given the Food and Drug Administration's (FDA's) acceptance of master protocol designs in recent guidance documents, the oncology field is rapidly moving to address the paradigm shift to molecular subtype focused studies. Identifying new “marker‐based” treatments requires new methodologies to address the growing demand to conduct clinical trials in smaller molecular subpopulations, identify effective treatment and marker interactions, and control for false positives. We introduce our methodology, Hierarchical Bayesian Clustering Design of Multiple Biomarker Subgroups (HCOMBS), a two‐stage umbrella Phase II design with effect size clustering and information borrowing across multiple biomarker‐treatment pairs. HCOMBS was designed to reduce required sample size, differentiate between varying effect sizes, and control for operating characteristics in the multi‐arm setting. When compared to independently applied Simon's Optimal two‐stage design, we showed through simulations that HCOMBS required less participants per treatment arm with a well‐controlled family‐wise error rate and desirable marginal power. Additionally, HCOMBS features a statistical approach that simultaneously conducts clustering and hypothesis testing in one step. We also applied the proposed design on the alliance brain metastases umbrella trial.
Correlation of chemotherapy delivery and survival outcomes of follicular lymphoma in the immunchemotherapy era.
Smith, Brian J., Thompson, Carrie A. , Wudhikarn, Kitsada , Button, Anna M. , Smith, Brian J., Habermann, Thomas M. , Cerhan, James R. , Link, Brian K.

Mayo Clinic

Journal of Clinical Oncology | March 12, 2020 | Volume: 31 | Issue: 15_suppl | Pages: 8563-8563

10.1200/jco.2013.31.15_suppl.8563 Get It

8563 Background: Optimal initial treatment of follicular lymphoma (FL) is unknown. Rituximab as monotherapy (R) or as a component of immunochemotherapy (R+Chemo) is established as effective and it is now reasonable to re-examine the role of chemotherapy dosing. We explored clinical features, systemic treatment and chemotherapy delivery with comparative effectiveness of delivered dose intensity (DDI) on outcomes. Methods: We reviewed the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource database along with medical records on newly diagnosed grade I-IIIa FL who received systemic therapy from 2002 to 2009. Presenting clinicopathologic factors, outcomes and systemic therapy details including doses of chemotherapy were collected. The event-free (EFS) and overall survival (OS) effects of systemic therapy and chemotherapy DDI were analyzed with multivariate Cox regression. Confounding effects of FLIPI, grade, stage, and age were considered in the analysis. Results: From 2002 to 2009, 631 newly diagnosed FL were enrolled. Median follow up duration was 52.7 months. We identified 322 grade I-IIIa FL treated with systemic therapy including 93 R and 229 R+Chemo. Age and stage were similarly distributed between the R and R+Chemo groups; however, patients in the R group had lower grade (p<0.01) and FLIPI (p=0.03). Multivariate analysis showed no significant differences in EFS (HR=1.24, p=0.28) or OS (HR=0.55, p=0.13) for R compared to R+Chemo. Among R-CVP or R-CHOP treated FL, DDI data were collected for 73 doxorubicin (dox) and 137 cyclophosphamide (cyc) patients. Eighty-five percent of patients received 90% or more pre-planned DDI. After controlling for confounding factors, higher cycDDI was associated with improved EFS (HR 0.55, P=0.04) and OS (HR 0.74, P=0.03). No significant OS or EFS effects of doxDDI were observed. Conclusions: Addition of chemotherapy to rituximab was not associated with a detectable difference in survival outcomes in grade I-IIIa FL at a median follow-up of 52.7 months. Among R+Chemo treated FL, chemotherapy was delivered completely in most patients and more completed delivery of cyclophosphamide was associated with improved EFS and OS.
Determinants of and outcomes associated with chemoimmunotherapy dose density in elderly subjects with diffuse large B-cell lymphoma (DLBCL).
Perepu, Usha , Weibel, Kelcy C, Jacobus, Laura, Smith, Brian, Button, Anna M. , Smith, Brian, Cerhan, James R. , Link, Brian K.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: 8061-8061

10.1200/jco.2012.30.15_suppl.8061 Get It

8061 Background: RCHOP is the standard first line therapy for DLBCL but elderly patients often receive suboptimal doses. Relative dose intensity (RDI) less than 70-90% has previously been associated with inferior survival in CHOP treated patients. We now investigate the clinical determinants of immunochemotherapy dose delivery and comparative effectiveness of dose intensity on lymphoma-specific outcomes in persons over the age of 60. Methods: SPORE MER (Molecular Epidemiology Resource) is a prospectively accrued observational study in which University of Iowa and Mayo Clinic patients with a diagnosis of Non Hodgkins lymphoma have been enrolled since 2003. We reviewed data from the Iowa patients along with medical records from DLBCL patients over the age of 60 treated with anthracycline based chemo immunotherapy consecutively enrolled up through to December 2009. Statistical tests of associations between RDI and clinicopathologic factors, as well as survival outcomes, were performed. Results: We identified 92 patients over the age of 60. The median age was 70. 47 subjects experienced at least 1 dose reduction, 26 subjects had dose delays, and 20 subjects were unable to complete therapy. RDI ranged from 0.30-1.70 (median 0.92) for doxorubicin and from 0.29-1.70 (median 0.97) for cyclophosphamide. 24 and 19% of subjects received < 80% of RDI for dox and cy respectively. Age (p< 0.001 for both dox and cy) and performance status (p=0.04 for dox) but not number of medications, ACE27 co-morbidity score, body surface area, nor need for acute care visits were associated with decreased RDI. Adjusted for IPI, RDI did NOT have a significant effect on event-free or lymphoma-specific survival. Conclusions: Among clinical variables, age is the dominant variable associated with delivery dose intensity for chemotherapy in elderly patients treated for DLBCL; and among elderly patients receiving chemo immunotherapy, we did not find an association between dose intensity and lymphoma-specific outcomes. [Table: see text]
Differences in the patterns of presentation and treatment between proximal and distal gastric cancers
Wilkinson, Neal, Howe, J., Patel‐Parekh, Lina, Smith, Brian E., Scott‐Conner, Carol E. H., Jp, Donohue, Donohue, J.

Mayo Clinic

Journal of Clinical Oncology | March 9, 2020 | Volume: 24 | Issue: 18_suppl | Pages: 4022-4022

10.1200/jco.2006.24.18_suppl.4022 Get It

4022 Background: While the overall incidence of gastric cancer has declined in the United States, the incidence of proximal gastric cancers has increased. Understanding the differences between proximal and distal gastric cancer, may enable us to identify important risk factors and treatment patterns. Methods: Data on 6099 patients diagnosed with gastric adenocarcinoma were collected as a Patient Care Evaluation under the auspices of the American College of Surgeons Commission on Cancer. Clearly defined proximal and distal cancers were compared using the Pearson chi-square test and logistic regression. Results: The proximal cancer group included 1924 patients (87% cardia; 13% fundus) and the distal cancer group included 1312 patients (85% antrum; 15% pylorus). Proximal gastric cancers occurred more often in men (p<0.0001), whites (compared to Black, Hispanic, Native American and Asian races) (p<0.0001), and at younger age (p<0.0001) compared to distal cancers. Risk factors for proximal presentation included tobacco use (Hazard ratio (HR) 1.9, p= 0.002) alchohol use (HR 1.5, p= 0.038) and Barretts (HR 2.7, p<0.0001). Risk factors for distal presentation included H. Pylori (HR 2.3, p= 0.001). Despite increased use of multi-modality therapy, fewer proximal gastric cancers underwent resection compared to distal cancers (p<0.0001). Conclusions: Different risk factors can be identified for proximal and distal gastric cancers, which can impact on risk reduction, screening efforts and help define the pathogenesis of gastric cancer. While proximal cancer patients receive more aggressive multimodality treatments, including adjuvant and neoadjuvant therapy, fewer undergo surgical resection. Long term survival based upon proximal and distal tumor differences will be explored when follow-up data become available.Key Words: gastric adenocarcinoma, proximal gastric cancer, distal gastric cancer, risk factors, treatment. [Table: see text] No significant financial relationships to disclose.
A phase II trial of pharmacological ascorbate, gemcitabine, and nabpaclitaxel for metastatic pancreatic cancer.
Smith, Brian J., Vollstedt, Sandy , Chandler, Meghan L. , Kasi, Pashtoon Murtaza , Bodeker, Kellie L. , Berg, Daniel , Chandrasekharan, Chandrikha , Sharif, Saima , Smith, Brian J., Brown, Heather A. , Cullen, Joseph J

Mayo Clinic

Journal of Clinical Oncology | February 4, 2020 | Volume: 38 | Issue: 4_suppl | Pages: TPS791-TPS791

10.1200/jco.2020.38.4_suppl.tps791 Get It

TPS791 Background: FOLFIRINOX or gemcitabine/nab-paclitaxel are both frontline chemotherapy options for patients with metastatic pancreas cancer. For most who cannot tolerate the triplet, the latter doublet is the preferred option. Through previous work by our group, pharmacologic ascorbate is known to synergize with gemcitabine; preliminary in vitro data from our group suggests a similar synergistic response with paclitaxel. Though ascorbate has been utilized in cancer therapy, few robust trials have investigated intravenous delivery of ascorbate to deliver plasma concentrations that are cytotoxic to tumor cells. Our prior studies have demonstrated ascorbate induces oxidative stress and cytotoxicity in pancreatic cancer cells; this cytotoxicity appears to be greater in tumor vs. normal cells. We hypothesize that production of hydrogen peroxide mediates the increased susceptibility of pancreatic cancer cells to ascorbate-induced metabolic oxidative stress, resulting in improved treatment outcomes, which has led to the development of the clinical trial (NCT02905578). Methods: All participants receive gemcitabine (1000 mg/m2 weekly) and nab-paclitaxel (125 mg/m2) on cycle days 1, 8, and 15 of a 28-day cycle. Participants are randomized to ± pharmacologic ascorbate (75-gram infusion 3x weekly) in addition to chemotherapy. Study therapy continues until tumor progression. The primary objective is to determine overall survival in patients when treated with combination gemcitabine, nab-Paclitaxel and high-dose ascorbic acid compared to gemcitabine and nab-paclitaxel in patients with non-resectable pancreatic cancer. Secondary objectives include determining objective response rate as well as progression free survival using RECIST 1.1 criteria employing a blinded reviewer for RECIST measurements. The study opened to accrual in 2018 with a goal of enrolling 65 participants. Oversight.Study is conducted under IND 105715 (J. Cullen, sponsor). The University of Iowa Biomedical IRB (IRB-01) serves as the IRB of record. Clinical trial information: NCT02905578.
Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
Strouse, Christopher , Rutherford, Sarah C. , Smith, Brian J, Lossos, Izidore S. , Thompson, Carrie A. , Friedberg, Jonathan W. , Cohen, Jonathon B. , Chapman, Jennifer R. , McDonnell, Timothy J. , Flowers, Christopher R. , Martin, Peter , Strouse, Christopher S , Smith, Brian J, Jaye, David L. , Kahl, Brad S. , Feldman, Andrew L. , Casulo, Carla , Syrbu, Sergei , Witzig, Thomas E. , Nastoupil, Loretta J. , Larson, Melissa C. , Habermann, Thomas M. , Slager, Susan L. , Cerhan, James R. , Link, Brian K.

Mayo Clinic

Blood | November 14, 2019 | Volume: 134 | Issue: Supplement_1 | Pages: 1610-1610

10.1182/blood-2019-126068 Get It

INTRODUCTION Complete staging via bone marrow assessment is standard of practice for most newly diagnosed non-Hodgkin lymphoma (NHL) patients, though the methods and patterns of bone marrow assessment vary in clinical practice. The 2014 Lugano Classification recommends that in diffuse large B cell lymphoma (DLBCL), positron emission tomography-computed tomography (PET/CT) alone can designated advanced-stage disease in many, but not all cases. For most other NHL subtypes, obtaining bone marrow biopsy (BMB) remains recommended. We aimed to assess clinical practice patterns of marrow assessment and the performance of PET/CT in the clinical setting. METHODS The Lymphoma Epidemiology of Outcomes (LEO) cohort is a prospective cohort from 8 academic medical centers. All patients were enrolled in the cohort within 6 months of diagnosis, and prospectively followed. Patients with lymphoma enrolled in the cohort between July 2015 and June 2017 were included for study. Baseline clinical characteristics at diagnosis, whether BMB and/or PET/CT were performed, and the result of these assessments were extracted from the database. Bone marrow involvement on PET/CT was abstracted via review of radiology reports. No central review of images was utilized. RESULTS In total, 3,251 patients were included, consisting of the following subtypes: DLBCL (n=1,098), follicular lymphoma (FL n=730), mantle cell lymphoma (MCL n=302), T-cell lymphoma (TCL n=278), marginal zone lymphoma (MZL n=269), other NHL (n=505) and composite lymphoma (n=69). Other clinical characteristics are shown in table 1. Staging BMB was obtained in 78% of patients, PET/CT was obtained in 56%, both BMB and PET/CT were obtained in 46% while neither were obtained in 9% (table 1). There were significant differences in lymphoma subtype between patients having any bone marrow assessment vs no bone marrow assessment (p<0.0001). MCL (96%) and DLBCL (94%) most frequently had any bone marrow assessment, while MZL was least frequently assessed (84%). Patients undergoing any bone marrow assessment had higher median lactate dehydrogenase (247 U/L vs 206 U/L, p=0.0002). Among the 8 enrolling medical centers, the frequency of bone marrow biopsy at diagnosis ranged from 53% to 86%, and the frequency of PET/CT at diagnosis ranged from 34% to 94% (p<0.0001, table 1). Among patients with DLBCL who had positive bone marrow by either PET/CT or BMB (N=107), 41% (44/107) were positive by BMB only, 19% (20/107) were positive by PET/CT only, and 40% (43/107) were positive by both. Figure 1 shows results of similar analyses for FL, MCL, MZL, and TCL. Using BMB as a gold standard for marrow involvement, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of PET/CT for marrow assessment in DLBCL is 49%, 90%, 68% and 91%, respectively. Data for other subtypes are shown in table 2. Patients undergoing both PET/CT and BMB had lower median LDH (231 U/L vs 254 U/L, p=0.0032) than those undergoing one or neither assessments. CONCLUSION Overall, 91% of all patients with newly diagnosed NHL had bone marrow assessments via either PET/CT, BMB or both. The significant variation in the frequency of BMB and PET/CT use among the 8 centers reflects a lack of clear consensus on staging practices regarding bone marrow assessment. The sensitivity of PET/CT for detection of marrow involvement was less than 50% across all subtypes. It is possible the sensitivity of PET/CT could be improved via a centralized review process of the images, as is performed in some clinical trials, however practical approaches for implementing such reviews in clinical practice have not been developed. Between 92-100% of all positive bone marrows were detected by BMB, except in cases with DLBCL in which 19% of positive bone marrows were missed by BMB but detected by PET/CT. Thus, in our analysis, BMB more reliably captured marrow involvement that PET/CT in all subtypes in which both assessments were performed. However, neither PET/CT nor BMB alone were able to identify all cases of bone marrow involvement and use of both modalities may be necessary in cases where marrow involvement would have clinically important implications. Disclosures Rutherford: Juno Therapeutics Inc: Consultancy, Honoraria; Janssen Scientific Affairs: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; Verastem: Consultancy, Honoraria; Karyopharm: Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Heron: Consultancy, Honoraria. Kahl:ADC Therapeutics: Consultancy, Research Funding; Seattle Genetics: Consultancy; TG Therapeutics: Consultancy; BeiGene: Consultancy. Lossos:Janssen Scientific: Membership on an entity's Board of Directors or advisory committees; NIH: Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees. Friedberg:Acerta: Other: Data & Safety Monitoring Committee; Bayer: Honoraria, Other: Data & Safety Monitoring Committee. Casulo:Celgene: Research Funding; Roche: Other: Travel, accommodation, expenses; Gilead: Honoraria, Other: Travel, accommodation, expenses. Cohen:Astra Zeneca: Research Funding; Takeda Pharmaceuticals North America, Inc.: Research Funding; Hutchison: Research Funding; Gilead/Kite: Consultancy; Bristol-Meyers Squibb Company: Research Funding; LAM Therapeutics: Research Funding; UNUM: Research Funding; Lymphoma Research Foundation: Research Funding; ASH: Research Funding; Seattle Genetics, Inc.: Consultancy, Research Funding; Janssen Pharmaceuticals: Consultancy; Genentech, Inc.: Consultancy, Research Funding. Nastoupil:TG Therapeutics: Honoraria, Research Funding; Novartis: Honoraria; Spectrum: Honoraria; Celgene: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Genentech, Inc.: Honoraria, Research Funding; Gilead: Honoraria; Bayer: Honoraria. Flowers:Denovo Biopharma: Consultancy; Spectrum: Consultancy; National Cancer Institute: Research Funding; Optimum Rx: Consultancy; Burroughs Wellcome Fund: Research Funding; Acerta: Research Funding; Bayer: Consultancy; BeiGene: Consultancy, Research Funding; Eastern Cooperative Oncology Group: Research Funding; TG Therapeutics: Research Funding; Genentech, Inc./F. Hoffmann-La Roche Ltd: Consultancy, Research Funding; Gilead: Consultancy, Research Funding; Karyopharm: Consultancy; AstraZeneca: Consultancy; Pharmacyclics/Janssen: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; V Foundation: Research Funding; Millenium/Takeda: Research Funding; Celgene: Consultancy, Research Funding. Cerhan:Janssen: Membership on an entity's Board of Directors or advisory committees; Celgene: Research Funding; NanoString: Research Funding. Martin:Sandoz: Consultancy; Karyopharm: Consultancy; Celgene: Consultancy; Teneobio: Consultancy; I-MAB: Consultancy; Janssen: Consultancy.
Improved diagnosis of Parkinson's disease from a detailed olfactory phenotype
Gerkin, Richard C. , Hentz, Joseph G. , Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Caviness, John N., Dugger, Brittany N. , Belden, Christine M. , Smith, Brian H. , Sue, Lucia I., Davis, Kathryn, Zamrini, Edward , Beach, Thomas G. , Driver-Dunckley, Erika, Adler, Charles H. , Sabbagh, Marwan Noel , Serrano, Geidy E. , Dugger, Brittany N

Mayo Clinic

Annals of Clinical and Translational Neurology | September 8, 2017 | Volume: 4 | Issue: 10 | Pages: 714-721

10.1002/acn3.447 | PMID 29046880 Get It

AbstractObjectiveTo assess the predictive potential of the complete response pattern from the University of Pennsylvania Smell Identification Test for the diagnosis of Parkinson's disease.MethodsWe analyzed a large dataset from the Arizona Study of Aging and Neurodegenerative Disorders, a longitudinal clinicopathological study of health and disease in elderly volunteers. Using the complete pattern of responses to all 40 items in each subject's test, we built predictive models of neurodegenerative disease, and we validated these models out of sample by comparing model predictions against postmortem pathological diagnosis.ResultsConsistent with anatomical considerations, we found that the specific test response pattern had additional predictive power compared with a conventional measure – total test score – in Parkinson's disease, but not Alzheimer's disease. We also identified specific test questions that carry the greatest predictive power for disease diagnosis.InterpretationOlfactory ability has typically been assessed with either self‐report or total score on a multiple choice test. We showed that a more accurate clinical diagnosis can be made using the pattern of responses to all the test questions, and validated this against the “gold standard” of pathological diagnosis. Information in the response pattern also suggests specific modifications to the standard test that may optimize predictive power under the typical clinical constraint of limited time. We recommend that future studies retain the individual item responses for each subject, and not just the total score, both to enable more accurate diagnosis and to enable additional future insights.